{"id":2176,"date":"2026-06-09T00:00:00","date_gmt":"2026-06-09T03:00:00","guid":{"rendered":"https:\/\/sevenresiduosaude.com.br\/blog\/?p=2176"},"modified":"2026-06-09T00:00:00","modified_gmt":"2026-06-09T03:00:00","slug":"pgrss-innovation-lab-pesquisa-pd-startup-spin-off-ip-patente","status":"publish","type":"post","link":"https:\/\/sevenresiduosaude.com.br\/blog\/pgrss-innovation-lab-pesquisa-pd-startup-spin-off-ip-patente\/","title":{"rendered":"PGRSS innovation: P&D, startup, spin-off"},"content":{"rendered":"

A regula\u00e7\u00e3o brasileira de RSS \u00e9 frequentemente subaproveitada por gestores hospitalares que reduzem PGRSS a opera\u00e7\u00e3o cl\u00ednica tradicional<\/strong>. Em 2026, h\u00e1 uma transforma\u00e7\u00e3o acelerada \u2014 hospitais com innovation lab<\/strong> + P&D pesquisa translacional<\/strong> + startup health-tech spin-off<\/strong> + IP propriedade intelectual<\/strong> + patente farma\/dispositivo\/algoritmo<\/strong> geram fluxos at\u00edpicos de RSS. A consequ\u00eancia \u00e9 a pr\u00e1tica de hospitais que otimizam apenas para fluxo assistencial<\/strong> + ignoram fluxos pesquisa\/inova\u00e7\u00e3o<\/strong> + subdimensionam OGM\/c\u00e9lulas\/biotech<\/strong> + perdem ativos intang\u00edveis<\/strong>. A realidade \u00e9 exatamente o oposto. PGRSS innovation opera em 5 dimens\u00f5es inova\u00e7\u00e3o<\/strong> \u2014 P&D pesquisa translacional bench-to-bedside + startup health-tech spin-off + IP patente farma\/dispositivo + algoritmo IA\/digital health + biotech OGM\/c\u00e9lulas\/terapia avan\u00e7ada.<\/p>\n

Para o gestor que opera ou planeja innovation lab hospitalar, \u00e9 fundamental dimensionar PGRSS espec\u00edfico desde o in\u00edcio.<\/p>\n

As 5 dimens\u00f5es PGRSS innovation<\/h2>\n

Em uma opera\u00e7\u00e3o hospitalar com innovation lab, o PGRSS tem 5 dimens\u00f5es.<\/p>\n\n\n\n\n\n\n\n\n\n
Dimens\u00e3o<\/th>\nStakeholder<\/th>\nFrequ\u00eancia<\/th>\nParticularidade<\/th>\n<\/tr>\n<\/thead>\n
P&D translacional<\/td>\nCRO+CEP+CONEP<\/td>\nDi\u00e1ria<\/td>\nBench-to-bedside<\/td>\n<\/tr>\n
Startup spin-off<\/td>\nAceleradora+VC+CVC<\/td>\nMensal<\/td>\nHealth-tech<\/td>\n<\/tr>\n
IP patente<\/td>\nINPI+escrit\u00f3rio+RFB<\/td>\nTrimestral<\/td>\nFarma+dispositivo<\/td>\n<\/tr>\n
Algoritmo IA<\/td>\nLGPD+ANPD+dados<\/td>\nDi\u00e1ria<\/td>\nDigital health<\/td>\n<\/tr>\n
Biotech OGM<\/td>\nCTNBio+ANVISA+CIBio<\/td>\nSemanal<\/td>\nC\u00e9lulas+terapia<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

A soma t\u00edpica \u00e9 5 dimens\u00f5es integradas<\/strong> em hospital com innovation lab maduro vs apenas P&D em hospital tradicional.<\/p>\n

P&D translacional: o est\u00e1gio bench-to-bedside<\/h2>\n

A primeira camada \u00e9 P&D translacional. Padr\u00e3o setorial inclui (a) pesquisa b\u00e1sica bench<\/strong> com cultura celular + animais experimenta\u00e7\u00e3o + bioterismo + Lei Arouca 11.794\/2008 + CEUA Comit\u00ea \u00c9tica Uso Animal; (b) pesquisa cl\u00ednica bedside<\/strong> com Fase I primeira-em-humanos + Fase II efic\u00e1cia + Fase III multic\u00eantrico + Fase IV p\u00f3s-marketing + Resolu\u00e7\u00e3o CNS 466\/2012; (c) CRO Contract Research Organization<\/strong> com Quintiles + Parexel + Covance + IQVIA + Syneos + ICON + outsourcing protocolo; (d) CEP\/CONEP<\/strong> comit\u00ea \u00e9tica pesquisa institucional + comiss\u00e3o nacional \u00e9tica pesquisa Plataforma Brasil; (e) descarte P&D<\/strong> com cultura celular + animal LERMS + biot\u00e9rio + RSS pesquisa espec\u00edfico.<\/p>\n

Hospital com P&D translacional maduro acelera bench-to-bedside<\/strong> + gera publica\u00e7\u00e3o alto impacto<\/strong> + atrai grant CNPq\/CAPES\/FAPESP<\/strong>. Como discutimos no post sobre PGRSS pesquisa<\/a>, translacional \u00e9 estrat\u00e9gico.<\/p>\n

Startup health-tech spin-off: o est\u00e1gio empreendedor<\/h2>\n

A segunda camada \u00e9 startup spin-off. Padr\u00e3o setorial inclui (a) aceleradora corporate<\/strong> com hospital Albert Einstein eHealth + S\u00edrio-Liban\u00eas InovHC + InCor InovaHC + Hospital Israelita; (b) VC\/CVC venture capital<\/strong> com Kaszek + Monashees + General Atlantic + Mau\u00e1 + Endeavor + Sa\u00fade Capital + corporate venture hospital pr\u00f3prio; (c) spin-off<\/strong> desmembramento empresa-m\u00e3e + cap table + valuation + tag-along + drag-along + ROFR; (d) due diligence pr\u00e9-investment<\/strong> com t\u00e9cnica + jur\u00eddica + cont\u00e1bil + ambiental + LGPD + dados pacientes; (e) descarte startup<\/strong> com sandbox prot\u00f3tipo + teste cl\u00ednico piloto + RSS startup espec\u00edfico + IP segregado.<\/p>\n

Hospital com startup spin-off maduro monetiza inova\u00e7\u00e3o<\/strong> + diversifica receita<\/strong> + atrai talento empreendedor<\/strong>. Conex\u00e3o com PGRSS internacionaliza\u00e7\u00e3o<\/a>.<\/p>\n

IP patente farma\/dispositivo: o est\u00e1gio propriedade intelectual<\/h2>\n

A terceira camada \u00e9 IP patente. Padr\u00e3o setorial inclui (a) patente farma INPI<\/strong> com pedido provis\u00f3rio + ordin\u00e1ria + PCT internacional + entrada nacional 30 pa\u00edses + extens\u00e3o pedi\u00e1trica; (b) patente dispositivo m\u00e9dico<\/strong> com ANVISA Classe I\/II\/III\/IV + INMETRO + ABNT + ISO 13485 + Marca CE Europa + FDA 510(k); (c) algoritmo IA\/digital health<\/strong> com software como dispositivo m\u00e9dico SaMD + IMDRF + classifica\u00e7\u00e3o risco + ANVISA Resolu\u00e7\u00e3o RDC 657 + LGPD; (d) escrit\u00f3rio IP<\/strong> com Dannemann + Di Blasi + Kasznar Leonardos + agente patente + custo R$ 25k-R$ 200k pedido; (e) monetiza\u00e7\u00e3o IP<\/strong> com licenciamento + royalty + cess\u00e3o + venda + colateral garantia opera\u00e7\u00e3o.<\/p>\n

Hospital com IP patente maduro gera royalty 3-15% receita<\/strong> + cria barreira competitiva<\/strong> + atrai parceria farma<\/strong>. Conex\u00e3o com auditoria controle<\/a>.<\/p>\n

Tr\u00eas perfis de PGRSS por maturidade innovation<\/h2>\n

Hospital sem innovation.<\/strong> 0 dimens\u00f5es. Custo mensal R$ 0<\/strong> mas perda de inova\u00e7\u00e3o + futuro.<\/p>\n

Hospital P&D s\u00f3.<\/strong> 1-2 dimens\u00f5es. Custo mensal R$ 35.000-90.000<\/strong>, captura pesquisa.<\/p>\n

Hospital innovation completo 5 dim.<\/strong> P&D+startup+IP+IA+biotech + integra\u00e7\u00e3o com PGRSS governan\u00e7a ESG<\/a>. Custo mensal R$ 80.000-220.000<\/strong>, efic\u00e1cia 90%, ROI 1.500-5.000% via royalty + venda startup + IP.<\/p>\n

Os tr\u00eas erros que aparecem em innovation lab<\/h2>\n

O primeiro \u00e9 a mistura P&D + assistencial<\/strong>. Confunde rastreabilidade pesquisa + impossibilita publica\u00e7\u00e3o + viola\u00e7\u00e3o CEP.<\/p>\n

O segundo \u00e9 a falta de IP segregado pr\u00e9-publica\u00e7\u00e3o<\/strong>. Sem patente antes paper = perda IP + zero monetiza\u00e7\u00e3o + concorr\u00eancia copia.<\/p>\n

O terceiro \u00e9 a subdimensionamento biotech OGM\/c\u00e9lulas<\/strong>. Sem CTNBio + CIBio + CQB = n\u00e3o-conformidade biotecnologia + risco multa.<\/p>\n

A regula\u00e7\u00e3o de PGRSS innovation no Brasil est\u00e1 em fase de moderniza\u00e7\u00e3o t\u00e9cnica acelerada com hospital empreendedor como prioridade. As institui\u00e7\u00f5es que estruturam innovation lab desde o in\u00edcio \u2014 alinhadas com calend\u00e1rio 2026 de compliance<\/a> \u2014 atravessam o crescimento sem solavanco. Para gestores que precisam alinhar com gest\u00e3o paralela industrial, o portal Seven Res\u00edduos sobre servi\u00e7os completos<\/a> traz a perspectiva integrada. O INPI Patente<\/a> \u00e9 refer\u00eancia t\u00e9cnica nacional.<\/p>\n

Solicite cota\u00e7\u00e3o PGRSS innovation lab 5 dimens\u00f5es<\/a><\/strong> \u2014 cap\u00edtulo dedicado a P&D translacional bench-to-bedside CRO+CEP+CONEP+CEUA, startup spin-off aceleradora+VC+CVC+health-tech, IP patente INPI+ANVISA+FDA+royalty, algoritmo IA SaMD+LGPD+ANPD, biotech OGM+CTNBio+CIBio+terapia avan\u00e7ada.<\/p>\n","protected":false},"excerpt":{"rendered":"

PGRSS innovation lab: P&D + startup + spin-off + IP + patente. Veja.<\/p>\n","protected":false},"author":3,"featured_media":2175,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[3013,3015,2574,3014],"class_list":["post-2176","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-compliance-legislacao","tag-innovation","tag-patente","tag-pesquisa","tag-startup"],"_links":{"self":[{"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/posts\/2176","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/comments?post=2176"}],"version-history":[{"count":1,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/posts\/2176\/revisions"}],"predecessor-version":[{"id":4312,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/posts\/2176\/revisions\/4312"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/media\/2175"}],"wp:attachment":[{"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/media?parent=2176"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/categories?post=2176"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/tags?post=2176"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}